Philippines - English - FDA (Food And Drug Administration)

ambica international corporation; distributor: ambica international corporation - lactic acid , urea , propylene glycol , light liquid paraffin - topical cream - 1.6g/1.5g/1.5g/1.5g per 15 grams

Ireland - English - HPRA (Health Products Regulatory Authority)

ricesteele manufacturing ltd - paraffin, liquid - oral solution - 100 %v/v

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

titan ag pty ltd - nonyl phenol ethoxylate; alcohol ethoxylate; paraffinic oil - oil miscible liquid - nonyl phenol ethoxylate emulsifiers & surfactants-noni active 120.0 g/l; alcohol ethoxylate emulsifiers & surfactants active 120.0 g/l; paraffinic oil petroleum derivative-oil active 582.0 g/l - wetting agent - broadacre cropping including fallow | cotton defoliation | defoliant additive | herbicide additive | high volume spraying | hort - spreading agent | wetting agent (use as directed) | improve penetrating properties

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - light liquid paraffin; pigeon paramyxovirus-1 strain p201 (inactivated) - misc. vaccines or anti sera - light liquid paraffin ungrouped active 552.0 mg/ml; pigeon paramyxovirus-1 strain p201 (inactivated) virus active 1200.0 hau/ml - immunotherapy

United States - English - NLM (National Library of Medicine)

major pharmaceuticals - calcium acetate (unii: y882yxf34x) (calcium cation - unii:2m83c4r6zb) - calcium acetate 667 mg - calcium acetate, usp is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (esrd). pregnancy category c calcium acetate capsules contain calcium acetate. animal reproduction studies have not been conducted with calcium acetate, and there are no adequate and well controlled studies of calcium acetate use in pregnant women. patients with end stage renal disease may develop hypercalcemia with calcium acetate treatment [see warnings and precautions (5.1)] . maintenance of normal serum calcium levels is important for maternal and fetal well being. hypercalcemia during pregnancy may increase the risk for maternal and neonatal complications such as stillbirth, preterm delivery, and neonatal hypocalcemia and hypoparathyroidism. calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment. the effects of calcium acetate on labor and delivery are unknown. calcium acetate capsules

United States - English - NLM (National Library of Medicine)

jacksonville pharmaceuticals, inc. - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 400 ug - nitroglycerin lingual spray is indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. do not use nitroglycerin lingual spray in patients who are taking pde-5-inhibitors, such as avanafil, sildenafil, tadalafil, or vardenafil. concomitant use can cause severe hypotension, syncope, or myocardial ischemia [see drug interactions (7.1) ]. do not use nitroglycerin lingual spray in patients who are taking soluble guanylate cyclase (sgc) stimulators, such as riociguat. concomitant use can cause hypotension. nitroglycerin lingual spray is contraindicated in patients with severe anemia (large doses of nitroglycerin may cause oxidation of hemoglobin to methemoglobin and could exacerbate anemia). nitroglycerin lingual spray  may precipitate or aggravate increased intracranial pressure and thus should not be used in patients with possible increased intracranial pressure (e. g. cerebral hemorrhage or traumatic brain injury). nitroglycerin lingual spray is c

United States - English - NLM (National Library of Medicine)

theratechnologies inc. - tesamorelin acetate (unii: lgw5h38ve3) (tesamorelin - unii:mqg94m5eeo) - tesamorelin 1 mg in 1 ml - egrifta is indicated for the reduction of excess abdominal fat in hiv-infected adult patients with lipodystrophy. limitations of use: - long-term cardiovascular safety of egrifta has not been established. consider risk/benefit of continuation of treatment in patients who have not had a reduction in visceral adipose tissue. - egrifta is not indicated for weight loss management as it has a weight neutral effect. - there are no data to support improved compliance with anti-retroviral therapies in hiv-positive patients taking egrifta. egrifta is contraindicated in patients with: - disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumor/surgery, head irradiation or head trauma. - active malignancy. any preexisting malignancy should be inactive and its treatment complete prior to instituting therapy [see warnings and precautions (5.1)] . - known hypersensitivity to tesamorelin or the excipients in egrifta [see warnings and precautions (5.5)]. - pregnant women because mo

United States - English - NLM (National Library of Medicine)

aurobindo pharma limited - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperidone 0.25 mg - risperidone tablets are indicated for the treatment of schizophrenia. efficacy was established in 4 short-term trials in adults, 2 short-term trials in adolescents (ages 13 to 17 years), and one long-term maintenance trial in adults [see clinical studies (14.1)] . monotherapy risperidone tablets are indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in 2 short-term trials in adults and one short-term trial in children and adolescents (ages 10 to 17 years) [see clinical studies (14.2)] .  adjunctive therapy risperidone tablets adjunctive therapy with lithium or valproate are indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in one short-term trial in adults [see clinical studies (14.3)] . risperidone tablets are indicated for the treatment of irritability associated with autistic disorder, including symptoms of aggression towards others, deliberate se

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

genus pharmaceuticals ltd - liquid paraffin light - bath additive - 828mg/1gram

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - liquid paraffin light - bath additive - 63.4 %w/w